益生菌的功能基因导入和基因编辑

益生菌已经在临床和食品领域应用多年,其安全性和有效性已经获得人们的认可。随着分子生物学技术的发展,采用益生菌作为载体进行基因导入或基因编辑,这些遗传改造的益生菌一部分已经作为新的药品或疫苗进入到临床应用阶段。携带功能基因的益生菌定殖于肠道进行表达和缓慢释放,这类益生菌作为活体药物获得益生菌和功能基因的双重功效,可用于治疗某些疑难病症。携带蛋白质抗原基因的益生菌定殖于肠道进行表达,可诱导肠道黏膜免疫、细胞免疫和体液免疫,这是一条更安全的口服疫苗途径。成簇的规则间隔短回文重复序列(clustered regularly interspaced short palindromic repeats, CRISPR)及其相关蛋白(CRISPR-associated protein, Cas)以其高效与便捷性推动了益生菌基因编辑的发展。这篇综述介绍了CRISPR-Cas9操作系统在益生菌方面的应用。对传统遗传操作较难的益生菌采用CRISPR-Cas9技术进行基因编辑,使其基因敲除和基因突变,基因敲入和基因调控等更为简单、高效和易操作。这些CRISPR/Cas9、CRISPRa和CRISPRi技术在...     

CRISPR/Cas9高通量筛选技术与肿瘤治疗

成簇规律间隔短回文重复(clustered regularly interspaced short palindromic repeats, CRISPR),是细菌或古菌在与噬菌体长期生存进化获得的一种免疫系统. 根据Cas蛋白(CRISPR-associated protein)的不同,CRISPR系统可分为3种. 其中II型CRISPR/Cas9已被改造成为一种有效的基因编辑工具,并运用于多种物种基因的改造. 作为1种基因编辑的手段,CRISPR/Cas9技术通过诱导DNA双链断裂损伤,进一步干扰基因的表达. 与传统的基因编辑技术相比,CRISPR/Cas9技术显示出效率高、成本低和易操作等特点. 与此同时,二代测序技术的发展促进全基因组的解析. CRISPR技术结合高通量二代测序手段的使用,在肿瘤的治疗领域中已发挥出了独特的优势. 本文就近年来CRISPR/Cas9高通量筛选技术的发展,及其在肿瘤治疗过程中的应用进行综述.     

Activating natural product synthesis using CRISPR interference and activation systems in Streptomyces

The rise of antibiotic-resistant bacteria represents a major threat to global health, creating an urgent need to discover new antibiotics. Natural products derived from the genus Streptomyces represent a rich and diverse repertoire of chemical molecules from which new antibiotics are likely to be found. However, a major challenge is that the biosynthetic gene clusters (BGCs) responsible for natural product synthesis are often poorly expressed under laboratory culturing conditions, thus preventing the isolation and screening of novel chemicals. To address this, we describe a novel approach to activate silent BGCs through rewiring endogenous regulation using synthetic gene regulators based upon CRISPR-Cas. First, we refine CRISPR interference (CRISPRi) and create CRISPR activation (CRISPRa) systems that allow for highly programmable and effective gene repression and activation in Streptomyces. We then harness these tools to activate a silent BGC by perturbing its endogenous regulatory network. Together, this work advances the synthetic regulatory toolbox for Streptomyces and facilitates the programmable activation of silent BGCs for novel chemical discovery.     

A Novel Eukaryote-Like CRISPR Activation Tool in Bacteria: Features and Capabilities

CRISPR (clustered regularly interspaced short palindromic repeats) activation (CRISPRa) in bacteria is an attractive method for programmable gene activation. Recently, a eukaryote-like, σ⁵⁴-dependent CRISPRa system has been reported. It exhibits high dynamic ranges and permits flexible target site selection. Here, an overview of the existing strategies of CRISPRa in bacteria is presented, and the characteristics and design principles of the CRISPRa system are introduced. Possible scenarios for applying the eukaryote-like CRISPRa system is discussed with corresponding suggestions for performance optimization and future functional expansion. The authors envision the new eukaryote-like CRISPRa system enabling novel designs in multiplexed gene regulation and promoting research in the σ⁵⁴-dependent gene regulatory networks among a variety of biotechnology relevant or disease-associated bacterial species.     

CRISPR-derived genome editing technologies for metabolic engineering

In metabolic engineering, genome editing tools make it much easier to discover and evaluate relevant genes and pathways and construct strains. Clustered regularly interspaced palindromic repeats (CRISPR)-associated (Cas) systems now have become the first choice for genome engineering in many organisms includingindustrially relevant ones. Targeted DNA cleavage by CRISPR-Cas provides variousgenome engineering modes such as indels, replacements, large deletions, knock-in and chromosomal rearrangements, while host-dependent differences in repair pathways need to be considered. The versatility of the CRISPR system has given rise to derivative technologies that complement nuclease-based editing, which causes cytotoxicity especially in microorganisms. Deaminase-mediated base editing installs targeted point mutations with much less toxicity. CRISPRi and CRISPRa can temporarily control gene expression without changing the genomic sequence. Multiplex, combinatorial and large scale editing are made possible by streamlined design and construction of gRNA libraries to further accelerates comprehensive discovery, evaluation and building of metabolic pathways. This review summarizes the technical basis and recent advances in CRISPR-related genome editing tools applied for metabolic engineering purposes, with representative examples of industrially relevant eukaryotic and prokaryotic organisms.     

A Cas12a-based CRISPR interference system for multigene regulation in mycobacteria

Mycobacteria are responsible for a heavy global disease burden, but their relative genetic intractability has long frustrated research efforts. The introduction of clustered regularly interspaced short palindromic repeats (CRISPR) interference (CRISPRi) has made gene repression in mycobacteria much more efficient, but limitations of the prototypical Cas9-based platform, for example, in multigene regulation, remain. Here, we introduce an alternative CRISPRi platform for mycobacteria that is based on the minimal type V Cas12a enzyme in combination with synthetic CRISPR arrays. This system is simple, tunable, reversible, can efficiently regulate essential genes and multiple genes simultaneously, and works as efficiently in infected macrophages as it does in vitro. Together, Cas12a-based CRISPRi provides a facile tool to probe higher-order genetic interactions in mycobacteria including Mycobacterium tuberculosis (Mtb), which will enable the development of synthetically lethal drug targets and the study of genes conditionally essential during infection.     

Reduced apoptosis in Chinese hamster ovary cells via optimized CRISPR interference

Chinese hamster ovary (CHO) cells are widely used for biopharmaceutical protein production. One challenge limiting CHO cell productivity is apoptosis stemming from cellular stress during protein production. Here we applied CRISPR interference (CRISPRi) to downregulate the endogenous expression of apoptotic genes Bak, Bax, and Casp3 in CHO cells. In addition to reduced apoptosis, mitochondrial membrane integrity was improved and the caspase activity was reduced. Moreover, we optimized the CRISPRi system to enhance the gene repression efficiency in CHO cells by testing different repressor fusion types. An improved Cas9 repressor has been identified by applying C-terminal fusion of a bipartite repressor domain, KRAB–MeCP2, to nuclease-deficient Cas9. These results collectively demonstrate that CHO cells can be rescued from cell apoptosis by targeted gene repression using the CRISPRi system.     

CRISPR⁃Cas9技术在植物次生代谢物生产中的研究进展

基因编辑（gene editing）技术可以对目的基因进行定点插入、敲除和置换。基于CRISPR-Cas9的基因编辑技术是继锌指核酸酶和转录激活样效应物核酸酶之后的第3代基因编辑技术。近年来,CRISPR-Cas9系统作为研究的热点被广泛应用于医学、药学、植物学、动物学和微生物学等领域,但其在植物次生代谢物领域的应用还处于探索时期。阐述了基于CRISPR-Cas9基因编辑技术的发展历程、工作原理和几种常用的基因编辑方法及其应用实例,总结了CRISPR-Cas9技术在对植物次生代谢产物研究方面的应用。利用CRISPR-Cas9系统可对植物基因组进行定点敲除、突变和插入,以达到提高植物次生代谢物含量、改良作物品质和提高植物抗性等目的。该技术已在植物次生代谢物生物合成关键酶基因的编辑等方面显示出越来越重要的作用。     

应用CRISPRi技术敲低耻垢分枝杆菌异柠檬酸脱氢酶基因

成簇的规律间隔的短回文重复序列干扰(clustered regularly interspaced short palindromic repeat interference,CRISPRi)是一种新型转录抑制技术,该系统包含RNA介导的DNA内切酶dCas9和针对目的基因的特异性单向导RNA(single guide RNA,sgRNA),通过形成DNA识别复合物特异性识别相应DNA序列以抑制目的基因的转录。异柠檬酸脱氢酶(isocitrate dehydrogenase,ICD)是三羧酸循环中的关键代谢酶,在分枝杆菌的碳代谢过程中发挥重要作用。本研究利用CRISPRi高效抑制分枝杆菌特定基因表达的方法构建耻垢分枝杆菌icd敲低(icd knockdown,ICD-KD)株。定量聚合酶链反应(quantitative polymerase chain reaction,qPCR)和蛋白免疫印迹检测结果显示,耻垢分枝杆菌中icd转录水平与ICD蛋白表达水平显著下降,表明采用CRISPRi技术成功构建了耻垢分枝杆菌ICD-KD株。进一步研究ICD-KD株的生长情况,测定其在固体培养基点板及液体培养基中的生长曲线,结果均显示ICD-KD株生长速率明显减慢,同时菌体内ICD酶活显著降低,提示ICD对分枝杆菌的生长存活起重要作用。本研究使用CRISPRi技术快速构建了分枝杆菌必需基因的敲低菌株,为后续研究分枝杆菌ICD在碳源代谢通路中的功能和碳通量流向调控机制提供了重要基础。     

基于CRISPR-Cas9技术的基因治疗研究进展

CRISPR-Cas9系统是细菌在与噬菌体抗争的进化过程中产生的一种抵御外源DNA入侵的机制,能有效识别并剪切外源DNA。基于其识别切除外源DNA的原理,CRISPR-Cas9系统被开发成为新一代基因编辑工具。与ES打靶、ZFN、TALEN等技术途径相比,CRISPR-Cas9系统操作简便、效率高、成本低,有着极其广阔的应用前景。本文整理了近年内有关CRISPR-Cas9系统的最新文献报道,对该系统工作原理以及针对基因治疗的研究进展进行综述。     

Efficient multiplexed gene regulation in Saccharomyces cerevisiae using dCas12a

CRISPR Cas12a is an RNA-programmable endonuclease particularly suitable for gene regulation. This is due to its preference for T-rich PAMs that allows it to more easily target AT-rich promoter sequences, and built-in RNase activity which can process a single CRISPR RNA array encoding multiple spacers into individual guide RNAs (gRNAs), thereby simplifying multiplexed gene regulation. Here, we develop a flexible dCas12a-based CRISPRi system for Saccharomyces cerevisiae and systematically evaluate its design features. This includes the role of the NLS position, use of repression domains, and the position of the gRNA target. Our optimal system is comprised of dCas12a E925A with a single C-terminal NLS and a Mxi1 or a MIG1 repression domain, which enables up to 97% downregulation of a reporter gene. We also extend this system to allow for inducible regulation via an RNAP II-controlled promoter, demonstrate position-dependent effects in crRNA arrays, and use multiplexed regulation to stringently control a heterologous β-carotene pathway. Together these findings offer valuable insights into the design constraints of dCas12a-based CRISPRi and enable new avenues for flexible and efficient gene regulation in S. cerevisiae.     

Non-viral and viral delivery systems for CRISPR-Cas9 technology in the biomedical field

The clustered regularly interspaced short palindromic repeats(CRISPR)-associated protein 9(CRISPR-Cas9) system provides a novel genome editing technology that can precisely target a genomic site to disrupt or repair a specific gene. Some CRISPR-Cas9 systems from different bacteria or artificial variants have been discovered or constructed by biologists, and Cas9 nucleases and single guide RNAs(sgRNA) are the major components of the CRISPR-Cas9 system. These Cas9 systems have been extensively applied for identifying therapeutic targets, identifying gene functions, generating animal models, and developing gene therapies.Moreover, CRISPR-Cas9 systems have been used to partially or completely alleviate disease symptoms by mutating or correcting related genes. However, the efficient transfer of CRISPR-Cas9 system into cells and target organs remains a challenge that affects the robust and precise genome editing activity. The current review focuses on delivery systems for Cas9 mRNA, Cas9 protein, or vectors encoding the Cas9 gene and corresponding sgRNA. Non-viral delivery of Cas9 appears to help Cas9 maintain its on-target effect and reduce off-target effects, and viral vectors for sgRNA and donor template can improve the efficacy of genome editing and homology-directed repair. Safe, efficient, and producible delivery systems will promote the application of CRISPR-Cas9 technology in human gene therapy.